PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
03-Aug-2022 Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Businesswire
03-Aug-2022 Global Cancer Therapies Market Research Report 2022 - ResearchAndMarkets.com Businesswire
03-Aug-2022 AmerisourceBergen Reports Fiscal 2022 Third Quarter Results Businesswire
03-Aug-2022 India Generic Drugs Market Research Report 2022: Small Molecule Generics v/s Biosimilars - Forecast to 2028 - ResearchAndMarkets.com Businesswire
03-Aug-2022 Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference Businesswire
03-Aug-2022 United Therapeutics Corporation Reports Second Quarter 2022 Financial Results Businesswire
03-Aug-2022 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
03-Aug-2022 Global Pharmaceutical Logistics Market Research Report 2022: Need for Pharmaceutical Shipments to Be Treated With the Utmost Care and Meet Certain Regulatory Requirements Driving Growth - ResearchAndMarkets.com Businesswire
03-Aug-2022 Global Artificial Intelligence in Healthcare Diagnosis Market Research Report 2022: Rising Adoption of Healthcare Artificial Intelligence in Research Areas Boosting Sector Growth - ResearchAndMarkets.com Businesswire
03-Aug-2022 SpectrumX Partners With Leading UK Specials Group to Accelerate Production of Anti-Pathogenic Drug for Clinical Trials Businesswire
03-Aug-2022 $964 Billion Worldwide Biotechnology Industry to 2027 - Featuring Amgen, Biogen, Novartis and Pfizer Among Others - ResearchAndMarkets.com Businesswire
03-Aug-2022 TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial Businesswire
03-Aug-2022 U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLITM* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®** Polpharma Biologics
03-Aug-2022 Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer Businesswire
03-Aug-2022 Curia ernennt Niall Condon zum President seiner Produktionssparte Businesswire
02-Aug-2022 Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides Businesswire
02-Aug-2022 Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 Businesswire
02-Aug-2022 Gilead Sciences Announces Second Quarter 2022 Financial Results Businesswire
02-Aug-2022 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of TuSimple Holdings Inc. (TSP) on Behalf of Investors Businesswire
02-Aug-2022 SpineGuard Announces the Revision of Its 2022 Financial Calendar Businesswire